Publications by authors named "Koenraad Bouman"
Article Synopsis
- * Two phase 2 clinical studies were conducted on the orally active factor D inhibitor danicopan, aiming to assess its impact on C3G and related conditions.
- * Although danicopan was found to be safe, it failed to provide consistent treatment benefits or sufficiently inhibit the alternative pathway, indicating that stronger and sustained action is needed for effective patient outcomes.
Baseline Clinical Characteristics and Complement Biomarkers of Patients with C3 Glomerulopathy Enrolled in Two Phase 2 Studies Investigating the Factor D Inhibitor Danicopan.
Steven D Podos Howard Trachtman Gerald B Appel Andrew S Bomback Bradley P Dixon Koenraad Peter Bouman
Am J Nephrol
January 2023
Article Synopsis
- C3 glomerulopathy (C3G) is a rare kidney disease caused by issues in the complement system, specifically the alternative pathway, and the study aimed to analyze biomarkers in patients participating in phase 2 trials of danicopan, a factor D inhibitor.
- Twenty-nine patients were evaluated, revealing systemic activation of the complement pathway with significant correlations between various complement biomarkers and kidney health metrics, such as eGFR and proteinuria.
- The findings highlight strong relationships between complement biomarkers and kidney function/histology, potentially enhancing the understanding and classification of C3G patients.
Background/aims: Vascular access thrombosis is one of the most morbid problems encountered by hemodialysis patients. Surveillance protocols utilizing venous pressure (Vp) and vascular access blood flow (VABF) measurements have been employed to preserve vascular access. We undertook a study to evaluate combined dynamic Vp and VABF measurements in the identification of vascular access impairment.
View Article and Find Full Text PDF